It acts
by selective inhibition of the serotonin reuptake pump, increasing
the extracellular catecholamines, such as serotonine, dopamine
and norepinephrine. In the human body FLX is metabolized to norfluoxetine (NFLX), its demethylated active metabolite (Table 1).